Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery

Rina Das1, Dinesh K Mehta1, Meenakshi Dhanawat1

  • 1MM College of Pharmacy, MM (Deemed to be University), Mullana, Ambala, HR, 133207, India.

Abstract

Insights

Quinazoline derivatives show significant promise as anticancer agents, acting through multiple mechanisms to combat various tumors. Further research into these compounds could lead to improved chemotherapy options and enhanced efficacy against cancer.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Cancer remains a leading cause of mortality globally, driving the need for novel and safer chemotherapeutic agents.
  • Existing anticancer drugs often exhibit significant side effects, highlighting the challenge of reducing cytotoxicity to normal cells.
  • The quinazoline scaffold and its derivatives have emerged as a promising class of compounds with demonstrated anticancer activities.

Purpose of the Study:

  • To review and synthesize recent advancements in the anticancer activity of quinazoline derivatives.
  • To explore novel aspects and future directions for developing quinazoline-based anticancer agents.
  • To highlight the therapeutic potential of quinazoline derivatives in cancer treatment.

Main Methods:

  • Comprehensive literature review of recent studies on quinazoline derivatives with anticancer potential.
  • Detailed analysis of the mechanisms of action of various quinazoline derivatives.
  • Focus on quinazoline moiety and its role in anticancer efficacy.

Main Results:

  • Quinazoline derivatives exhibit anticancer potential through diverse mechanisms, including inhibition of DNA repair enzymes.
  • These derivatives effectively inhibit Epidermal Growth Factor Receptor (EGFR) and thymidylate enzymes.
  • Quinazoline derivatives also interfere with tubulin polymerization, crucial for cell division.

Conclusions:

  • Quinazoline derivatives represent a promising avenue for cancer therapy, acting via well-established mechanisms.
  • Further exploration of quinazoline derivatives holds significant potential for improving chemotherapy.
  • Undiscovered properties of quinazoline derivatives warrant further investigation to enhance their efficacy.

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K